Yumi Kambayashi Selected Research

Peplomycin

1/2017	Retrospective Investigation of Cutaneous Squamous Cell Carcinoma on the Lip Treated with Peplomycin Administered Through a Superficial Temporal Artery.
1/2015	Immunomodulatory effects of peplomycin on immunosuppressive and cytotoxic cells in the lesional skin of cutaneous squamous cell carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yumi Kambayashi Research Topics

Disease

41	Melanoma (Melanoma, Malignant) 08/2022 - 11/2015
31	Neoplasms (Cancer) 09/2021 - 01/2012
7	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 01/2022 - 01/2018
6	Mycosis Fungoides 01/2020 - 11/2013
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2020 - 01/2015
3	Neoplasm Metastasis (Metastasis) 09/2021 - 01/2021
3	Lymphoma (Lymphomas) 01/2020 - 01/2017
3	Extramammary Paget Disease (Paget Disease, Extramammary) 01/2018 - 11/2012
3	Carcinoma (Carcinomatosis) 01/2017 - 09/2012
3	Autoimmune Diseases (Autoimmune Disease) 01/2017 - 09/2012
3	Hemangiosarcoma (Angiosarcoma) 01/2013 - 01/2012
2	Lymphomatoid Papulosis 01/2022 - 02/2018
2	Psoriasis (Pustulosis Palmaris et Plantaris) 03/2021 - 05/2012
2	Fever (Fevers) 01/2021 - 06/2020
2	Sarcoma (Soft Tissue Sarcoma) 09/2020 - 05/2013
2	T-Cell Lymphoma (Lymphoma, T Cell) 01/2020 - 01/2019
2	Keratoacanthoma 01/2019 - 09/2017
2	Erythema 02/2018 - 09/2012
2	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2018 - 01/2017
2	Bullous Pemphigoid (Pemphigoid) 01/2018 - 01/2014
2	Pemphigus (Pemphigus Vulgaris) 01/2014 - 09/2013
1	Interstitial Nephritis (Tubulointerstitial Nephritis) 05/2022
1	Rheumatoid Arthritis 05/2022
1	COVID-19 01/2022
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2022
1	Atopic Dermatitis (Atopic Eczema) 01/2022
1	Drug Eruptions (Drug Eruption) 01/2022
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2022
1	Microcystic adnexal carcinoma 09/2021
1	Erythema Nodosum 11/2020
1	Adult-Onset Still's Disease 06/2020
1	Penile Neoplasms (Penile Cancer) 01/2020
1	Edema (Dropsy) 01/2020
1	Stewart Treves syndrome 01/2020
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2020
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2020
1	Lymphangiosarcoma 01/2020
1	Colorectal Neoplasms (Colorectal Cancer) 09/2019
1	Turcot syndrome 01/2019
1	Rhabdomyolysis 01/2019
1	Spontaneous Remission 01/2019
1	Microsatellite Instability 01/2019

Drug/Important Bio-Agent (IBA)

26	NivolumabIBA 01/2022 - 06/2016
13	IpilimumabIBA 09/2021 - 09/2016
10	AntibodiesIBA 08/2022 - 09/2017
10	dabrafenibIBA 05/2022 - 02/2018
10	trametinibIBA 05/2022 - 02/2018
10	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2018
8	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 05/2022 - 09/2017
8	ChemokinesIBA 01/2021 - 11/2015
6	Bexarotene (LGD1069)FDA Link 01/2022 - 01/2017
6	Immune Checkpoint InhibitorsIBA 01/2020 - 05/2017
5	Therapeutic UsesIBA 01/2020 - 11/2015
5	pembrolizumabIBA 01/2019 - 01/2018
4	binimetinibIBA 05/2022 - 06/2020
4	encorafenibIBA 05/2022 - 06/2020
4	RetinoidsIBA 01/2022 - 11/2013
4	Proto-Oncogene Proteins B-rafIBA 09/2021 - 01/2019
4	Denosumab FDA Link 01/2020 - 01/2017
4	mogamulizumabIBA 01/2020 - 01/2018
4	Interleukin-17 (Interleukin 17)IBA 01/2020 - 09/2012
3	Retinoid X Receptors (Retinoid X Receptor)IBA 01/2022 - 01/2018
3	PeriostinIBA 09/2021 - 01/2015
3	Biological ProductsIBA 09/2021 - 09/2016
3	Matrix Metalloproteinases (MMPs)IBA 09/2021 - 11/2012
3	InterferonsIBA 01/2021 - 11/2013
3	Messenger RNA (mRNA)IBA 01/2020 - 11/2015
3	RANK LigandIBA 01/2018 - 01/2016
2	MAP Kinase Kinase Kinases (MAP Kinase Kinase Kinase)IBA 09/2021 - 09/2019
2	Dacarbazine (DIC)FDA LinkGeneric 09/2020 - 01/2018
2	Etoposide (VP 16)FDA LinkGeneric 01/2020 - 01/2018
2	Histone Deacetylase InhibitorsIBA 09/2019 - 01/2019
2	Programmed Cell Death 1 ReceptorIBA 01/2019 - 01/2018
2	Imiquimod (Aldara)FDA LinkGeneric 01/2018 - 01/2017
2	Indicators and Reagents (Reagents)IBA 01/2018 - 01/2018
2	PeplomycinIBA 01/2017 - 01/2015
2	dermcidinIBA 11/2013 - 09/2011
2	Risedronic Acid (Actonel)FDA LinkGeneric 01/2013 - 01/2012
2	Diphosphonates (Bisphosphonates)IBA 01/2013 - 01/2012
2	Docetaxel (Taxotere)FDA Link 01/2013 - 01/2012
1	dupilumabIBA 01/2022
1	PlasminogenIBA 01/2021
1	Plasminogen Activator Inhibitor 1IBA 01/2021
1	Interferon Type IIBA 09/2020
1	Cytotoxins (Cytolysins)IBA 09/2020
1	AntigensIBA 09/2020
1	Methylprednisolone FDA LinkGeneric 01/2020
1	Interleukin-23 (Interleukin 23)IBA 01/2020
1	Histone Deacetylases (Histone Deacetylase)IBA 09/2019
1	Proteins (Proteins, Gene)FDA Link 01/2019
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2019
1	LigandsIBA 01/2019
1	CaspasesIBA 01/2019
1	MitogensIBA 01/2019

Therapy/Procedure

42	Therapeutics 08/2022 - 09/2011
8	Immunotherapy 01/2021 - 06/2016
5	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 09/2021 - 05/2017
4	Radiotherapy 05/2019 - 01/2012
3	Drug Therapy (Chemotherapy) 02/2021 - 01/2017
1	Radical Mastectomy 01/2020